What is the evidence for OncuraKit's Stage I sensitivity of 81–97%?

The Stage I sensitivity figures come directly from two peer-reviewed publications by Yenos Analytical. The 2025 study (Rafiq A, Kanavarioti A, Int. J. Mol. Sci. 2025, 26(8), 3822; doi:10.3390/ijms26083822) enrolled newly diagnosed Stage I and Stage II cancer patients and reports per-marker accuracy: miR-21-5p = 93.8% (36/37 cancer samples identified), miR-375-3p = 81.5%, miR-141-3p = 97.3%. All enrolled cancer patients had Stage I or II disease at the time of testing. Zero healthy control samples exceeded the 1.5× HL threshold. The 2024 study (Non-Coding RNA 2024, 10(4):42) confirms the cancer vs. healthy level separation (1.83× HL vs 1.04× HL) with p=1.6×10⁻²².